Loading...
Invex Therapeutics Ltd
IXC.AX•ASX
Healthcare
Biotechnology
A$0.09
A$0.007(8.24%)
Invex Therapeutics Ltd (IXC.AX) Financial Performance & Income Statement Overview
Review Invex Therapeutics Ltd’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
164.06%
↑ 164.06%
Operating Income Growth
75.04%
↑ 75.04%
Net Income Growth
78.81%
↑ 78.81%
Operating Cash Flow Growth
64.42%
↑ 64.42%
Operating Margin
-9.61%
↓ 9.61%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
9.43%
↑ 9.43%
ROE
2.07%
↑ 2.07%
ROIC
-2.16%
↓ 2.16%
Invex Therapeutics Ltd (IXC.AX) Income Statement & Financial Overview
Review Invex Therapeutics Ltd's (IXC.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $1.21M | $0.00 | $459085.00 | $229543.00 |
| Cost of Revenue | $0.00 | $0.00 | $300412.00 | $150206.00 |
| Gross Profit | $1.21M | $0.00 | $158673.00 | $79337.00 |
| Gross Profit Ratio | $1.00 | $0.00 | $0.35 | $0.35 |
| R&D Expenses | $280874.00 | $1.76M | $3.80M | $1.90M |
| SG&A Expenses | $575667.00 | $731438.00 | $562403.00 | $431408.00 |
| Operating Expenses | $856541.00 | $2.49M | $4.36M | $2.56M |
| Total Costs & Expenses | $856541.00 | $2.49M | $4.36M | -$2.40M |
| Interest Income | $115176.00 | $376642.00 | $449133.00 | $224567.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | -$355715.00 | $2.49M | $3.90M | -$39586.00 |
| EBITDA | -$741366.00 | $376643.00 | -$9952.00 | $1112.00 |
| EBITDA Ratio | -$0.61 | $0.00 | -$9.50 | $0.005 |
| Operating Income | $355715.00 | -$2.49M | -$4.36M | -$1.95M |
| Operating Income Ratio | $0.29 | $0.00 | -$9.50 | -$8.50 |
| Other Income/Expenses (Net) | -$1.10M | $376643.00 | $449130.00 | $1112.00 |
| Income Before Tax | -$741366.00 | -$2.11M | -$3.91M | -$1.95M |
| Income Before Tax Ratio | -$0.61 | $0.00 | -$8.53 | -$8.50 |
| Income Tax Expense | -$1.21M | $376641.00 | -$12175.00 | $1112.00 |
| Net Income | $470890.00 | -$2.11M | -$3.90M | -$1.95M |
| Net Income Ratio | $0.39 | $0.00 | -$8.50 | -$8.50 |
| EPS | $0.006 | -$0.03 | -$0.05 | -$0.03 |
| Diluted EPS | $0.006 | -$0.03 | -$0.05 | -$0.03 |
| Weighted Avg Shares Outstanding | $75.45M | $75.15M | $75.15M | $75.15M |
| Weighted Avg Shares Outstanding (Diluted) | $75.44M | $75.15M | $75.15M | $75.15M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan